Last reviewed · How we verify
GW677954
At a glance
| Generic name | GW677954 |
|---|---|
| Also known as | Pioglitazone |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study In People With Type 2 Diabetes (PHASE2)
- Study In Patients With Dyslipidaemia (PHASE2)
- A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |